|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The double tumor suppressors ING4/PTEN could inhibit the growth of U87 glioma cells with a synergistic antitumor effect, and the RGD modification also acted as an anti-oncogene to inhibit U87 cell invasion and tumor angiogenesis.
|
28407709 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitor of growth 4 (ING4), a member of the ING family discovered in 2003, has been shown to act as a tumor suppressor and is frequently down-regulated in various human cancers.
|
30643005 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitor of growth 4 (ING4) is known as a tumor suppressor.
|
30390334 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our findings reveal a novel miR-29b/RARβ/ING4 pathway that regulates tumorigenic properties of Tsc2-deficient cells, and that may serve as a potential therapeutic target for TSC, lymphangioleiomyomatosis (LAM), and other mTORC1-hyperactive tumors.
|
31420607 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using prediction software, it was demonstrated that tumor suppressor ING4 was a target of miR‑214.
|
31059086 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitor of growth 4 (ING4) inhibits tumor growth via multiple pathways.
|
31849466 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, knockdown of FOXO3a attenuated not only ING4-elicited tumor suppression but also ING4-mediated regulatory effect on FOXO3a downstream targets, confirming that FOXO3a is involved in ING4-directed tumor-inhibitory effect in HCC.
|
30745827 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, expression of the tumor suppressor gene inhibitor of growth protein 4 (<i>ING4</i>) in cell lines was investigated using reverse transcription-quantitative polymerase chain reaction and western blotting. miR-650 overexpression promoted CRC cell proliferation and migration by targeting ING4 when the cells were transfected with the miR-650 mimics.
|
30008936 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CELSR2 and ING4 cytoplasmic expression was significantly stronger in tumors than in benign epithelial cells, while the nuclear expression of both markers was significantly stronger in benign epithelial cells than in tumors.
|
29489009 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nowadays, both inhibitor of growth 4 (ING4), as a multimodal tumor suppressor gene, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), as a potent apoptosis-inducing gene, are experiencing a renaissance in cancer gene therapy.
|
28925992 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitor of growth family member 4 (ING4) has been reported to function as a tumor suppressor and is involved in regulating cell cycle progression, apoptosis, cell migration and invasion.
|
29805679 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor inhibitor of growth 4 (ING4) regulates chromatin structure by recruiting the histone acetyl transferase complex HBO1 to sites with histone H3 trimethylated at K4.
|
27926782 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ING4 expression was not associated with sex, age or tumor volume (P>0.05), but was associated with the nuclear grade of renal cancer (P<0.0001), the clinical stage of CCRC (P<0.0001) and lymphatic metastasis (P<0.0001).
|
28781682 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ING4 might inhibit tumor proliferation and angiogenesis in human glioma.
|
28927128 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of this miRNA has been associated with downregulation of tumor suppressors ING4 and NDRG2, which have been implicated in cancer progression.
|
28101578 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a tumor suppressor, ING4 inhibits tumor growth, invasion, and metastasis by multiple signaling pathways.
|
26803518 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our results indicate that cancer gene therapy combining two or more tumor suppressors such as p53 and ING4 may constitute a novel and effective therapeutic modality for human breast cancer and other cancers.
|
26530780 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both inhibitor of growth 4 (ING4) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) are well known as tumor suppressors that are closely related to tumor occurrence and progression.
|
27421660 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ING4, a potential tumor suppressor, is implicated in cell cycle arrest, apoptosis, cell migration and angiogenesis.
|
27806345 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, ING4 obviously suppressed LoVo CRC subcutaneously xenografted tumor growth and reduced tumor MVD in vivo in athymic BALB/c nude mice.
|
26936485 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor weights were used to calculate the inhibition rate, and the expression levels of ING4 and P53 were detected by reverse transcription‑polymerase chain reaction.
|
27484725 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitor of growth 4 (ING4) is a candidate tumor suppressor which plays an important role in multiple processes including DNA repair, apoptosis, cell cycle control, tumor metastasis and angiogenesis.
|
27466989 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitor of growth 4 (ING4) is a tumor suppressor.
|
25790869 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On the basis of this evidence, it is believed that cancer gene therapy combining two tumor suppressors such as ING4 and PTEN can be used to establish an effective and novel therapeutic strategy for nasopharyngeal carcinoma and other cancers.
|
25571952 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ING4 as a novel member of ING family has potential tumor-suppressive effects via multiple pathways.
|
25326586 |
2015 |